Slide 1: Q1'24 Earnings Presentation
Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO Q1’24 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer May 7, 2024
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified b
Slide 3: CEO Summary: Q1'24 Highlights
CEO Summary: Q1’24 Highlights Strong gross margin performance and focus on efficiency to support ongoing investments in growth Income Statement Components ($ in millions except percentages) Q1' 2024 Q1'2023 Revenue 24.5 30.0 Gross Margin 14.8 18.3 % of Revenue 60.3% 61.2% Operating (Loss) Profit (2.
Slide 4: Q1'24 Revenue by Geography
Q1’24 Revenue by Geography As Reported Americas EMEA APAC • Overall: Down 6.6% as reported • Overall: Down 16% reported, includes 1% FX • Overall: Down 35.4% reported vs record PY headwind Pre-clinical: Continued down on tight • Pre-clinical: Slow in Covid related Respiratory • products • Pre-clinic
Slide 5: New Product Introductions: Focused on Commercialization
New Product Introductions: Focused on Commercialization Established base platform targets market growth; exciting new growth opportunities in bio-production and cellular EXPAND TO STRENGTHEN THE BASE INNOVATE CELLULAR BIO-PRODUCTION PRECLINICAL CMT CMT- ORGANOIDS • Extend leadership in telemetry wit
Slide 6: Financials
6 Financials 6
Slide 7: Q1'24 Performance vs. Q1'23 (GAAP except where noted)
Q1’24 Performance vs. Q1’23 (GAAP except where noted) $ in millions except per share data REVENUE GROSS MARGIN ADJUSTED EBITDA* $4.8 $1.6 DILUTED (LOSS) EARNINGS CASH FLOW FROM OPERATIONS NET DEBT* PER SHARE GAAP Adjusted* Q1’24 Q1’23 Q1’24 Q1’23 * Non-GAAP measure, see Appendix for reconciliation t
Slide 8: Outlook
8 Outlook 8
Slide 9: 2024 Full Year Outlook: 'A Tale of Two Halves'
2024 Full Year Outlook: ‘A Tale of Two Halves’ For FY2024, we expect: ▪ Revenues approximately flat for the full year vs. prior year ▪ Weakness in the first half versus a strong prior year comparison ▪ Second half growth versus both first half of 2024 and the second half of 2023, supported by new pr
Slide 10: Appendix
10 Appendix
Slide 11: Reconciliation to GAAP P&L
Reconciliation to GAAP P&L (1) Other operating expenses include a $0.5 million commission paid in connection with the receipt of employee retention credits and an estimated loss of $0.5 million related to an unclaimed property audit. (2) Adjusted income taxes includes the tax effect of adjusting for
Slide 12: Slide 12